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Pharmacological treatments to improve functional outcomes after stroke remain limited beyond the use of thrombo-
lytic agents during the first few hours. As our understanding of 
regenerative mechanisms that underlie the recovery of func-
tion matures, it is expected that approaches to target long-term 
recovery will receive increasing attention.1 This study focuses 
on GSK249320, a monoclonal antibody that blocks the axon 
outgrowth inhibition molecule, myelin-associated glycopro-
tein (MAG). Brain levels of MAG spontaneously increase 
after a stroke.2 The putative mechanism of action for this MAG 
antibody is the disinhibition of neurite sprouting and growth, 
thus allowing new neuronal connections to be formed.3
Many neurophysiological and neuroanatomical events 
related to behavioral recovery have been described in the days 
to weeks after a stroke. After focal ischemic infarct in pri-
mary motor cortex (M1) in both rodents and nonhuman pri-
mates, motor representations in spared cortical areas undergo 
functional reorganization in parallel with motor recovery.4,5 
Furthermore, growth-promoting and growth-inhibiting genes 
are upregulated in spared neural tissue both adjacent to the 
infarct and in more remote areas connected with infarct.2,6,7 
Finally, axonal sprouting and the formation of new cortico-
cortical connections occur after focal cortical infarcts.8,9 Thus, 
it is reasonable to presume that pharmacological agents that 
Background and Purpose—New insights into the brain’s ability to reorganize after injury are beginning to suggest novel 
restorative therapy targets. Potential therapies include pharmacological agents designed to promote axonal growth. The 
purpose of this study was to test the efficacy of one such drug, GSK249320, a monoclonal antibody that blocks the axon 
outgrowth inhibition molecule, myelin-associated glycoprotein, to facilitate recovery of motor skills in a nonhuman 
primate model of ischemic cortical damage.
Methods—Using a between-groups repeated-measures design, squirrel monkeys were randomized to 1 of 2 groups: an 
experimental group received intravenous GSK249320 beginning 24 hours after an ischemic infarct in motor cortex with 
repeated dosages given at 1-week intervals for 6 weeks and a control group received only the vehicle at matched time 
periods. The primary end point was a motor performance index based on a distal forelimb reach-and-retrieval task. 
Neurophysiological mapping techniques were used to determine changes in spared motor representations.
Results—All monkeys recovered to baseline motor performance levels by postinfarct day 16. Functional recovery in the 
experimental group was significantly facilitated on the primary end point, albeit using slower movements. At 7 weeks 
post infarct, motor maps in the spared ventral premotor cortex in the experimental group decreased in area compared with 
the control group.
Conclusions—GSK249320, initiated 24 hours after a focal cortical ischemic infarct, facilitated functional recovery. Together 
with the neurophysiological data, these results suggest that GSK249320 has a substantial biological effect on spared 
cortical tissue. However, its mechanisms of action may be widespread and not strictly limited to peri-infarct cortex and 
nearby premotor areas.   (Stroke. 2015;46:1620-1625. DOI: 10.1161/STROKEAHA.114.008088.)
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promote neurite sprouting and growth might amplify these 
events and thereby increase the extent of behavioral recovery 
during this period.
Previous studies in rodents have demonstrated that a MAG 
antibody can neutralize MAG-mediated inhibition and pro-
mote neurite outgrowth associated with improved behavioral 
recovery after injury to the cerebral cortex.3,10 A study in 47 
healthy human subjects found GSK249320 to be well toler-
ated in doses ≤25 mg/kg body weight.11 A recent clinical trial 
enrolled 42 patients 24 to 72 hours after stroke onset and found 
GSK249320 to be safe.12 The primary goal of this study was 
to evaluate the efficacy of GSK249320 for enhancing recovery 
of skilled use of the forelimb in a nonhuman primate model 
of focal cortical ischemia and to determine whether its effects 
are evident in the organization of movement representations in 
spared cortical areas.
Methods
Nine adult male squirrel monkeys were used in this study. All experi-
ments were conducted in accordance with institutional and federal 
guidelines for care and use of experimental animals and with approval 
from the Institutional Animal Care and Use Committee. A procedural 
timeline is presented in Figure 1. Monkeys were assigned randomly 
to 1 of 2 groups, differing only with regard to whether they received 
postinfarct injections of GSK249320 (experimental group) or vehicle 
(control group). One investigator was wholly responsible for animal 
behavioral training and postinfarct testing and was blind to the treat-
ment condition. Each monkey underwent preinfarct training on a pel-
let retrieval task for 10 days, and then probe trials were conducted 
once per week for 2 weeks.13 Next, monkeys underwent the first of 2 
surgical procedures. In the first procedure, the distal forelimb (DFL) 
representations in primary motor cortex (M1), dorsal premotor cortex 
(PMd), and ventral premotor cortex (PMv), as well as the surround-
ing proximal representations, were identified by intracortical micro-
stimulation mapping techniques. Then, a cortical infarct that targeted 
80% of the M1 DFL was created by electrocoagulation of surface 
vasculature (Figure 2). After recovery from anesthesia, monkeys were 
returned to their home cages.
The active drug, identified as GSK249320 and supplied by GSK, 
United Kingdom, is an antibody to MAG. It binds with human MAG 
or its monkey ortholog with similar affinity (data on file). GSK249320 
(30 mg/kg per dose; experimental group) or vehicle (control group) 
was administered intravenously every 7 days for 7 weeks, beginning 
24 hours after infarct. Postinfarct behavioral performance on the re-
trieval task was assessed weekly on days after the injections. Then, 
in a second surgical procedure, intracortical microstimulation map-
ping was repeated to verify the extent of the infarct and to determine 
whether motor representations were altered. After a 2-week survival 
period, animals were humanely euthanized and the brains were re-
moved for histological analysis.
The primary end point was a function of the number of finger flex-
ions required to retrieve a pellet (flexions per retrieval performance in-
dex) measured during probe sessions. Secondary end points included 
retrieval success rate, time required to perform different phases of the 
retrieval task, and frequency of aiming errors, again measured dur-
ing the probe sessions. Statistical tests included repeated-measures 
ANOVA and Bonferroni post hoc comparisons maintaining α-level at 
0.05. Group averages are reported as mean+SEM. Additional details 
can be found in the online-only Data Supplement.
Results
Infarct Size and Location
The mean extent of the infarct across the cortical surface was 
12.03±1.04 mm2 in the experimental group and 10.97±1.07 
mm2 in the control group. There was no statistically signifi-
cant difference between groups in the absolute lesion size: 
t(5)=0.69; P=0.52 (Figure 3). The M1 DFL damage relative to 
each monkey’s baseline DFL was 81.5±1.61% for the experi-
mental group and 79.1+0.98% for the control group, closely in 
line with our 80% target (Figure 2). There was no statistically 
significant difference between groups in the relative lesion 
size: t(5)=1.136; P=0.31. As intended, all infarcts spared DFLs 
at the rostral edge of the M1 DFL, as well as a small portion 
located medial and lateral to the infarct region. No damage 
was evident in PMd or PMv.
Behavioral Assessment of Skilled Hand Use
There was a significant effect of group (F[1,5]=12.732; 
P=0.001), time (F[8,40]=15.696; P<0.0001), and group X 
time interaction (F[8,40]=5.899; P<0.0001) in the primary 
end point, flexions per retrieval performance index. Bonferroni 
multiple comparison tests revealed significant group differ-
ences on days 3 (t[1,40]=6.95; P=0.009) and 9 (t[1,40]=3.86; 
P=0.018). That is, performance was better in the experimen-
tal group on day 3 (experimental group=1.55+0.22; control 
group=3.44+0.73) and day 9 (experimental group=1.01+0.06; 
control group=1.92+0.60). On day 3, there was no over-
lap between the groups. There were no differences between 
groups before the infarct or on day 16 through 44 (Figure 4A).
With respect to secondary end points, there was a signifi-
cant effect of group (F[1,5]=8.48; P=0.01), time (F[3,15]=5.54; 
P=0.0092), and group X time interaction (F[3,15]=6.537; 
P=0.0048) for time in well. Bonferroni multiple comparison test 
revealed that the experimental group required significantly more 
time (3.17±0.71) than the control group (0.93±0.22) on day 3 only 
(t[1,15]=5.70; P<0.0004; Figure 4B). Assessing reach and retrieval 
times separately, there was a significant effect of time for both 
reach (F[3,15]=8.217; P=0.0018) and retrieval (F[3,15]=12.904; 
P=0.0002) but there was no effect of group nor group X time inter-
action. Bonferroni comparisons indicate that time to reach was sig-
nificantly greater on day 3 than on preinfarct day 1 (t[1,15]=4.39; 
P=0.003) and day 2 (t[1,15]=4.03; P=0.0066), as well as day 9 
(t[1,15]=3.57; P=0.0168). Retraction time was greater on days 3 
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Figure 1. Timeline of experimental procedures. In the figure and 
throughout the text, experimental (Exp) time periods are refer-
enced to the number of days or weeks relative to the infarct; 
that is, week -6=6 weeks before infarct. Baseline behavioral 
performance was defined by 2 motor testing sessions during 
weeks -3 and -2. After an intracortical microstimulation map-
ping procedure and infarct (time, 0), each monkey received 7 
weekly injections of GSK249320 or vehicle beginning 24 hours 
post infarct. Behavioral testing occurred weekly beginning on 
day 3; filled circle: drug or vehicle injection and open triangles: 
behavioral testing session. Cont indicates control; and HP, hand 
preference testing.
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and 9 compared with preinfarct days 1 and 2. Other significant 
differences included day 3 versus preinfarct day 1 (t[1,15]=4.69; 
P=0.0018) and preinfarct day 2 (t[1,15]=5.16; P=0.0006); day 9 
versus preinfarct day 1 (t[1,15]=3.42; P=0.0228) and preinfarct 
day 2 (t[1,15]=3.90; P=0.0084). Days 3 and 9 were not signifi-
cantly different: (t[1,15]=1.27; P>0.9999).
There was also a significant effect of time for aiming errors 
(F[3,15]=12.904; P=0.0028). Bonferroni comparisons indi-
cated that the average aiming errors for all monkeys were 
greater than preinfarct measures on days 3 and 9. There was 
no significant effect of group nor group X time interaction 
in aiming errors: day 3 versus preinfarct day 1 (t[1,15]=3.0; 
P=0.054) and preinfarct day 2 (t[1,15]=3.60; P=0.0156). Day 
9 versus preinfarct day 1 (t[1,15]=3.60; P=0.0156) and prein-
farct day 2 (t[1,15]=3.626; P=0.0150). Days 3 and 9 were not 
significantly different: (t[1,15]=0.022; P>0.9999).
Postinfarct Changes in Spared Motor 
Representations
Forelimb movements typically were evoked throughout the 
peri-infarct M1, PMd DFL, and PMv DFL at low current levels 
(Figure 2). In addition, forelimb movements could be evoked 
from sites along the border of the infarcted territory. However, 
because these sites were typically no >250 µm from the bor-
der and current thresholds were relatively high (often 25–30 
µA), these sites were eliminated from the analyses because 
the evoked movements were likely due to current spread into 
the spared tissue. In 3 of the intracortical microstimulation 
mapping procedures, proximal but not DFL movements were 
evoked in PMd (baseline maps: Exp-3, Cont-3; postinfarct 
maps: Cont-3). This lack of distal movements at threshold 
current levels is not unusual in PMd of squirrel monkeys, and 
thus, these data were retained for the statistical analyses. DFL 
movements were observed at threshold currents in each of the 
PMv mapping procedures.
Area means (±SEM) for the DFLs before and after the infarct 
are presented in Table. In the peri-infarct M1 DFL, there were 
no statistically significant differences between groups (group 
effect: F(1,5=0.0068, P=0.9374; time effect: F(1,5)=2.0365, 
P=0.2129; group X time interaction: F(1,5)=0.21374, 
P=0.6633). In the PMd DFL, there were no statistically signifi-
cant differences between groups (group effect: F[1,5]=2.7294, 
P=0.1594; time effect: F[1,5]=3.0600, P=0.1407; group X 
time interaction: F[1,5]=1.0144, P=0.3601). It should be 
noted though that PMd DFL increased in each of the 4 mon-
keys in the experimental group but in only one of the 3 mon-
keys in the control group (χ2=9.561; P=0.002). In PMv, there 
was no group (F[1,5]=0.5553; P=0.4897) nor time effect 
(F[1,5]=0.1821; P=0.6873), but there was a significant group 
X time interaction (F[1,5]=11.0953; P=0.0208). Bonferroni 
multiple comparison tests revealed a decrease in PMv DFL 
in the experimental group after the infarct (experimental pre- 
versus experimental postinfarct area), but this difference was 
not significant [t(1,5)=2.87; P=0.07]. There was also no sig-
nificant difference between the pre- and post control group 
maps (t[1,5]=1.92; P=0.112; Figure 5).
Figure 2. Sequence of photographs of surface vasculature in frontal cortex before (left), immediately after (middle), and 7 weeks 
after (right) an ischemic infarct in M1 distal forelimb (DFL; case control [Cont]-1). Left, Vascular pattern with superimposed move-
ment representations in M1, dorsal premotor cortex (PMd), and ventral premotor cortex (PMv). M1 DFL (≈80%) was targeted for the 
infarct based on intracortical microstimulation (ICMS) maps of evoked movements (movement coding: red=digit; green=wrist/forearm; 
purple=proximal+wrist/forearm; yellow=digit+wrist; and grey=proximal). Dashed white line indicates intended infarct territory. In the case 
illustrated here, a large vein that bisected the DFL was intentionally spared but not its branches. White box encloses the enlarged region 
shown in middle and right images. Middle, Ischemic region in M1 DFL several minutes after the infarct was completed. The ischemic area 
is readily distinguishable because of blanching of the tissue. Visual glare is because of the presence of saline on the brain surface dur-
ing the procedure. This infarct technique produces sharply defined borders between ischemic and normally perfused tissue (indicated by 
blue boundary) and creates an infarct through all 6 layers of cerebral cortex but spares the underlying white matter. Right, Photograph of 
ischemic region 7 weeks after the infarct in M1 DFL. As intended, the perimeter of the M1 DFL, as well as PMd and PMv (not shown), was 
spared by the infarct, as evidenced by ICMS-evoked movements. Scale bar, 500 µm.
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Figure 3. Lesion size in experimental (Exp) and control (Cont) 
groups. There were no statistical differences in either absolute or 
relative lesion size between groups. DFL indicates distal forelimb.
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Because of the significant interaction effect in PMv and 
the potential for differential effects between PMv and PMd 
in experimental versus control groups, we also examined 
PMv–PMd difference scores. A 2-way ANOVA revealed a 
significant group X time interaction (F[1,5]=8.75; P=0.0308). 
Bonferroni adjusted multiple comparisons showed that for 
the experimental group, the baseline PMv–PMd difference 
scores were greater than the postinfarct difference scores 
(t[1,5]=3.678; P=0.0286). There was no prepost differ-
ence in PMv–PMd difference scores for the control group 
(t[1,5]=0.7557; P=0.9678).
Discussion
Loss of function after stroke is due not only to the local isch-
emic damage, but also to a large extent, a disconnection of 
functional neural networks throughout the brain. Therefore, 
investigations into various therapeutic strategies to improve 
motor function after stroke have targeted interventions 
thought to promote neural reorganization, restoring functional 
connectivity within the spared motor networks. Many recent 
restorative therapies have targeted myelin-associated axon 
outgrowth inhibition molecules, inhibitors that promote a non-
permissive growth environment after stroke, reducing neurite 
outgrowth,14,15 thus constraining neural plasticity and limit-
ing recovery.16 One current putative intervention strategy is to 
neutralize such inhibition, thereby promoting axonal growth 
and sprouting to restore movement-related communication in 
cortical networks. Of the various myelin-associated inhibitors, 
MAG is of interest as it has been shown to be upregulated in 
peri-infarct tissue after ischemic damage in the aged brain.2 
This study examined the efficacy of a new monoclonal anti-
body, GSK 249320, to MAG (ie, MAG antibody) in squir-
rel monkeys for recovery after an ischemic infarct in M1. A 
pilot experiment conducted before this study demonstrated 
that after cortical infarcts in M1 of squirrel monkeys, MAG 
antibody was present within the infarcted tissue within hours 
after a single administration (Figure I in the online-only Data 
Supplement).
With an infarct targeting of 80% of the M1 DFL, the deficit 
was transient in both groups. However, GSK249320, initiated 
intravenously 24 hours after the infarct, facilitated more rapid 
recovery of DFL motor function, including the primary end 
point, flexions per retrieval performance index. The experi-
mental group demonstrated superior motor performance on 
the reach-and-retrieval task on day 3 (2 days after initial treat-
ment) and day 9 (1 day after second treatment). In fact, the 
deficit was unusually mild in the experimental group even on 
day 3. This rapid recovery in motor skill is somewhat surpris-
ing given the putative effects of MAG antibody on axonal 
growth promotion. However, evidence from other studies sug-
gests that, in addition to blocking MAG-mediated inhibition 
of neurite outgrowth, treatment with MAG antibody protects 
oligodendrocytes from oxidative-stress induced cell death.3 
Because oligodendrocytes play a critical role in axonal integ-
rity and are particularly sensitive to ischemic injury,17,18 it is 
possible that treatment with GSK249320 in this study exerted 
its therapeutic benefits through protection of oligodendrocytes 
in the vicinity of the infarct. There is also evidence suggest-
ing that MAG antibody may enhance synaptic plasticity. In 
the mature central nervous system, MAG receptors, such as 
NgR1 (part of the Nogo receptor family), maintain synaptic 
stability by inhibiting dendritic changes in morphology and 
function, such as long-term potentiation.19,20 Blocking these 
pre- and postsynaptic inhibitory receptors could account for 
an immediate activity-dependent modulation of synaptic con-
nections supporting a rapid increase in functional recovery.
Comparing neurophysiological map changes revealed 
unexpected findings. Given that MAG is known to be 
upregulated in peri-infarct cortex,2 it might be expected that 
GSK249320 would have its greatest effect in the 20% of the 
Table.  Size of Movement Representations Before and After 
Infarct (mm2)
Group
Peri-Infarct 
M1
Peri-Infarct 
M1 PMv PMv PMd PMd
Preinfarct Postinfarct Preinfarct Postinfarct Preinfarct Postinfarct
Exp 2.65±0.25 3.00±0.41 3.49±0.68 2.75±0.44 0.59±0.28 1.38±0.43
Cont 2.75±0.28 2.93±0.39 2.98±0.67 3.55±0.25 0.41±0.31 0.62±0.33
Cont indicates control; Exp, experiment; PMd, dorsal premotor cortex; and 
PMv, ventral premotor cortex.
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Figure 4. Motor performance. A, Flexions per retrieval performance index. The control (Cont) group was significantly more impaired than 
the experimental (Exp) group on days 3 and 9. B, Retrieval time index. The Exp group took more time to retrieve food pellets from the 
Klüver board on postinfarct day 3 than the Cont group. The infarct had no significant effect on flexion time for a successful retrieval for the 
Cont group. *Indicates significant difference between groups (post hoc test, P<0.05). Small circles (Exp) and triangles (Cont) correspond 
to individual case data. Individual data are shown only for days 3 and 9 as the variance was small on the other days, and small circles 
would overlap. Error bars, mean±SEM.
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M1 DFL spared by the infarct. However, although the peri-
infarct M1 DFL increased slightly in both experimental and 
control groups (0.35 mm2 in Exp; 0.18 mm2 in Cont), there 
was no significant difference between groups (P=0.93). Thus, 
if the behavioral benefit seen with GSK249320 is based on 
expansion of DFL representation in peri-infarct cortex, then 
it is likely to be due to some other neuroanatomical or neu-
rophysiological change. Similarly, PMd DFL maps did not 
change significantly, although a larger sample size may yet 
reveal a group effect since in the present sample, P=0.16, with 
larger PMd DFL maps in the experimental group (Figure 5).
On the basis of our previous studies demonstrating an increase 
in PMv DFL after M1 infarct in squirrel monkeys not subjected 
to postinfarct intervention,5,8 we expected to see postinfarct 
expansions in both groups but larger increases in the experi-
mental group. We have also shown in a recent study that spared 
premotor representations expand as a function of rehabilitative 
training in a rat model of ischemic infarct.4 As expected, in this 
study, PMv DFL increased in size in each of the 3 control mon-
keys but decreased in size in each of the 4 experimental mon-
keys. On the basis of our historical data,5,8 the expected increase 
in PMv DFL in animals with an 80% infarct in the M1 DFL, but 
no rehabilitative training, is 33.4% at 3 months post infarct. In 
this study, the increase in PMv DFL representation in the con-
trol group was 17.5% at 7 weeks post infarct. Furthermore, we 
have shown in other studies that after M1 lesions, spared motor 
maps first decrease and then increase in size with increasing time 
after infarct.4,21 Given the longer survival times in the historical 
controls, the size of the increase in PMv DFL in control mon-
keys in this study is within the expected range. However, in the 
experimental group, PMv maps decreased by 19.2%. We have 
only observed decreases in PMv DFL when infarcts were <50% 
of the M1 DFL8 or were derived at much earlier time points 
after the infarct (<3 weeks).4,22 Because there is no evidence that 
GSK249320 affected lesion size, this result suggests that the drug 
treatment may have had an unusual effect on cortical motor net-
works to support recovery of DFL performance compared with 
what is typically observed during spontaneous recovery alone.
One possible explanation for the discrepant map results 
in PMv is that monkeys in the experimental group used a 
particularly successful compensatory reaching strategy. 
Although movement kinematics were not explicitly examined 
in this study, some support for a successful compensatory 
strategy in the experimental group can be derived from exami-
nation of the secondary behavioral end point, time in well. 
Although monkeys in the experimental group demonstrated 
superior scores on the flexions per retrieval performance index, 
they also spent more time with their digit(s) in the food well 
to perform retrievals on day 3. It is possible that slower and 
more deliberate movements were part of a compensatory strat-
egy that facilitated improvement. Furthermore, if monkeys in 
the experimental group differentially used proximal arm and 
shoulder muscles for reaching or stabilization, recovery may 
have been accompanied by an expansion of proximal fore-
limb representations at the expense of distal representations in 
PMv. Consistent with this hypothesis, examination of Figure 5 
reveals that at many specific sites, intracortical microstimula-
tion resulted in distal movements in the preinfarct map but 
proximal movements in the postinfarct map. This observation 
is most evident in the experimental group. Previous studies 
from this laboratory using a similar infarct model have shown 
that a variety of compensatory strategies are used soon after 
the infarct. The kinematic patterns that are eventually used 
after recovery often are different than those used before the 
infarct.23
 Alternatively, compensatory strategies could involve 
attentional or motivational mechanisms related to a more 
focused effort leading to more successful retrievals.
In a virtual lesion study in healthy humans using transcra-
nial magnetic stimulation, Davare et al24 provided evidence for 
a functional dissociation between PMd and PMv. Their results 
supported the view that PMv is involved more in the grasping 
component of a grip-lift task, whereas PMd is involved more 
in the lifting phase, recruiting more proximal muscles. If the 
trend toward larger distal representations in PMd and smaller 
distal representations in PMv with GSK249320 treatment is 
borne out in larger samples, then it is reasonable to suggest that 
the differential functional specialization of premotor areas in 
precision grasping is altered by postinfarct GSK249320. We 
propose that reorganization of spared cortical networks results 
in a functional rebalancing of premotor cortical areas, so that 
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Figure 5. Changes in size of distal forelimb representations. A, Ventral premotor cortex (PMv) distal forelimb (DFL) motor maps before 
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PMd assumes a greater role in the grasp phase and PMv in the 
lift-retrieval phase of the task.
In the context of the previous literature, the present results 
narrow the range of possibilities for the mechanisms underlying 
the functional benefits of GSK249320. Plasticity in peri-infarct 
M1 DFL is an unlikely candidate, unless a different neurophysi-
ological or neuroanatomical end point is needed to capture the 
effect of GSK249320. It is likely that compensatory kinematic or 
attentional strategies, supported by plasticity in premotor cortical 
areas, contributed to faster recovery in the experimental group. 
The best case can be made for plasticity in PMv, although PMd is 
still a potential site. In the future, larger studies should (1) expand 
on the present results to examine other premotor areas (PMd and 
the supplementary motor area) and (2) focus on kinematic end 
points. It would also be interesting to know whether GSK249320 
given to normal monkeys would affect the motor map representa-
tions in PMv and PMd similarly to what we have shown in the 
experimental group. As plasticity after neural injury is likely to be 
a network response, it is also possible that subcortical or contralat-
eral structures are involved. However, it is clear that GSK249320 
is safe in a nonhuman primate model of focal cortical ischemia, 
accelerates functional recovery, and has a significant effect on the 
neurophysiology of spared motor representations.
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